Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Phase 3

Completed

• Conditions: Pandemic Influenza
• Interventions: Biological: Monovalent A/H1N1 influenza vaccine

• Registration Number: NCT00970177
• Lead Sponsor: Novartis Vaccines

Brief Summary

This present study, randomized, single-blind, dose-ranging, multicenter study, will evaluate immunogenicity, safety and tolerability of two doses of an adjuvanted and not-adjuvanted new swine-origin influenza A/H1N1 virus monovalent subunit vaccine in healthy adult and elderly subjects. A booster dose will be administered 12 months after the first vaccination.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-08
• Study First Submitted: 2009-09-01
• Study First Submitted QC: 2009-09-01
• Study First Posted: 2009-09-02
• Primary Completion: 2009-10
• Study Completion: 2011-03
• Status Verified: 2016-11
• Last Update Submitted: 2016-11-30
• Last Update Posted: 2016-12-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 812

Inclusion Criteria

1. Males and females 18 years of age and above on the day of enrollment;
2. Individuals in good health
3. Individuals are able to comply with all study procedures
4. Willingness to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response.

Exclusion Criteria

1. Individual not able to comprehend and to follow all required study procedures;
2. History or any illness that might interfere with the results of the study or pose additional risk to the subjects due to participation in the study;
3. Any serious chronic or progressive disease according to judgment of the investigator
4. History of any anaphylaxis, serious vaccine reactions, to any excipients.
5. Adjuvanted influenza vaccine or documented confirmed or suspected influenza disease within 3 months prior to Day 1;
6. Receipt of another investigational agent within 4 weeks prior to enrollment, or before completion of the safety follow-up period in this or in another study; unwilling to refuse participation in another clinical study through the end of this study;
7. Any other vaccines within 4 weeks prior to enrollment or who are planning to receive any vaccine within 4 weeks from the study vaccines; only exception being plain seasonal influenza vaccines which are allowed until 1 week prior to and after 1 week study vaccinations.
8. Receipt of blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks;
9. Axillary temperature ≥ 38°C or oral temperature ≥ 38.5°C within 3 days of intended study vaccination;
10. Known or suspected impairment/alteration of immune function, for example resulting from a receipt of immunosuppressive therapy within 60 days prior to Visit 1;
11. History of progressive or severe neurological disorders;
12. Surgery planned during the study period that in the Investigator's opinion would interfere with the study visits schedule;
13. Female of childbearing potential, not used any acceptable contraceptive methods for at least 2 months prior to study entry;
14. Female pregnant or nursing (breastfeeding) mothers or females of childbearing potential do not plan to use acceptable birth control measures during the first 3 weeks after vaccination;
15. Members of the research staff or their relatives.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
low dose of antigen + low dose of adjuvant	Monovalent A/H1N1 influenza vaccine	-
high dose of antigen	Monovalent A/H1N1 influenza vaccine	-
high dose of antigen + high dose of adjuvant	Monovalent A/H1N1 influenza vaccine	-

Primary Outcome Measures

Name	Time	Method
To identify the preferred vaccine formulation, dosage (antigen & adjuvant), schedule (one or two administrations) of the H1N1 sw monovalent vaccine in adults.	43 days after first vaccination

Secondary Outcome Measures

Name	Time	Method
To evaluate immunogenicity against A/California H1N1sw strain after booster dose of egg-derived seasonal trivalent, MF59 adjuvanted vaccine Fluad, recommended for 2010/2011 season, administered 12 months after primary course according to CHMP criteria.	3 weeks after booster vaccination

Trial Locations

Locations (1)

Wurzburg, Fulda, Neumunster, Balve, Leipzig, Magdeburg; 🇩🇪 Munchen, Germany